Allogene Therapeutics Inc (ALLO)
US Market

Allogene Therapeutics (ALLO) Stock Price & Analysis


ALLO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.91 - $17.49
Previous Close$4.92
Average Volume (3M)1.89M
Market Cap
Enterprise Value$310.63M
Total Cash (Recent Filing)$517.32M
Total Debt (Recent Filing)$101.12M
Price to Earnings (P/E)-2.1
May 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding144,497,383
10 Day Avg. Volume1,712,141
30 Day Avg. Volume1,886,873
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)1.09
Price to Sales (P/S)2925.63
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.28K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.97
Price Target Upside253.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $4.91 and its highest was $17.49 in the past 12 months.
    What is Allogene Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Allogene Therapeutics Inc’s upcoming earnings report date?
    Allogene Therapeutics Inc’s upcoming earnings report date is May 10, 2023 which is in 42 days.
      How were Allogene Therapeutics Inc’s earnings last quarter?
      Allogene Therapeutics Inc released its earnings results on Feb 28, 2023. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.7 by $0.04.
        Is Allogene Therapeutics Inc overvalued?
        According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Allogene Therapeutics Inc pay dividends?
          Allogene Therapeutics Inc does not currently pay dividends.
          What is Allogene Therapeutics Inc’s EPS estimate?
          Allogene Therapeutics Inc’s EPS estimate is -$0.62.
            How many shares outstanding does Allogene Therapeutics Inc have?
            Allogene Therapeutics Inc has 144,497,380 shares outstanding.
              What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
              Allogene Therapeutics Inc reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.7. Following the earnings report the stock price went down -0.157%.
                Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
                Among the largest hedge funds holding Allogene Therapeutics Inc’s share is PRIMECAP Management Co. It holds Allogene Therapeutics Inc’s shares valued at 31M.


                  Allogene Therapeutics Stock Smart Score

                  The Allogene Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Allogene Therapeutics Inc

                  Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.


                  Top 5 ETFs holding ALLO

                  Market Value
                  Smart Score
                  Simplify Propel Opportunities ETF
                  Fidelity Nasdaq Composite Index ETF
                  iShares U.S. Tech Breakthrough Multisector ETF
                  Direxion Fallen Knives ETF
                  BMO MSCI Innovation Index ETF
                  Up to five ETFs with an Outperform Smart Score that hold ALLO. The ETFs are listed according to market value of ALLO within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Day One Biopharmaceuticals
                  Springworks Therapeutics
                  Rhythm Pharmaceuticals
                  Twist Bioscience
                  Rocket Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis